Survival outcomes in patients with high-risk neuroblastoma (HRNB) in remission after relapsed or refractory treatment receiving eflornithine (DFMO) maintenance.

被引：0
|
作者：
Sholler, Giselle Linda Saulnier
Ferguson, William
Bergendahl, Genevieve
Clinch, Thomas
Kraveka, Jacqueline M.
机构：
[1] Penn State Hlth Childrens Hosp, Hershey, PA USA
[2] St Louis Univ, St Louis, MO 63103 USA
[3] US WorldMeds, Louisville, KY USA
[4] Med Univ South Carolina, Charleston, SC 29425 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10060
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Matched external control analysis of event-free survival (EFS) in patients with high-risk neuroblastoma (HRNB) receiving eflornithine (DFMO) maintenance.
    Oesterheld, Javier E.
    Bergendahl, Genevieve
    Berry, Donald A.
    Lorenzi, Elizabeth
    Clinch, Thomas
    Kraveka, Jacqueline M.
    Ferguson, William
    Brown, Valerie I.
    Eslin, Don
    Hanson, Derek
    Harrod, Virginia Lynn
    Isakoff, Michael
    Mitchell, Deanna
    Wada, Randal
    Zage, Peter E.
    Sholler, Giselle Linda Saulnier
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [2] TOLERABILITY AND SAFETY OF EFLORNITHINE (DFMO) IN HIGH-RISK NEUROBLASTOMA (HRNB) PATIENTS TREATED WITH DFMO MAINTENANCE THERAPY
    Bergendahl, Genevieve
    Kraveka, Jacqueline
    Ferguson, William
    Moore, Abigail
    Clinch, Thomas
    Oesterheld, Javier
    Wada, Randal
    Isakoff, Michael
    Eslin, Don
    Brown, Valerie
    Roberts, William
    Zage, Peter
    Harrod, Virginia
    Mitchell, Deanna
    Hanson, Derek
    Sholler, Giselle Saulnier
    PEDIATRIC BLOOD & CANCER, 2023, 70
  • [3] COMPARISON OF EVENT FREE SURVIVAL (EFS) IN HIGH-RISK NEUROBLASTOMA (HRNB) PATIENTS RECEIVING EFLORNITHINE (DFMO) MAINTENANCE TO AN EXTERNAL CONTROL IMMUNOTHERAPY STUDY DATABASE
    Oesterheld, Javier
    Bergendahl, Genevieve
    Berry, Donald
    Lorenzi, Elizabeth
    Clinch, Thomas
    Kraveka, Jacqueline
    Ferguson, William
    Brown, Valerie
    Eslin, Don
    Hanson, Derek
    Harrod, Virginia
    Isakoff, Michael
    Mitchell, Deanna
    Wada, Randy
    Zage, Peter
    Sholler, Giselle Saulnier
    PEDIATRIC BLOOD & CANCER, 2022, 69
  • [4] MICE SENSITIVITY ANALYSIS OF EVENT FREE SURVIVAL IN HIGH-RISK NEUROBLASTOMA PATIENTS RECEIVING EFLORNITHINE (DFMO) MAINTENANCE TREATMENT WITH MATCHED EXTERNAL CONTROLS
    Kraveka, Jacqueline
    Oesterheld, Javier
    Ferguson, William
    Bergendahl, Genevieve
    Clinch, Thomas
    Staines, Harry
    Sholler, Giselle Saulnier
    PEDIATRIC BLOOD & CANCER, 2023, 70
  • [5] DFMO Maintains Remission in Relapsed/Refractory High Risk Neuroblastoma
    Sholler, Giselle Saulnier
    Ferguson, William
    Bergendahl, Genevieve
    Bond, Jeffrey
    Neville, Kathleen
    Eslin, Don
    Brown, Valerie
    Roberts, William
    Wada, Randy
    Oesterheld, Javier
    Mitchell, Deanna
    Foley, Jessica
    Zage, Peter
    Rawwas, Jawhar
    Sencer, Susan
    Kraveka, Jacqueline
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S46 - S47
  • [6] Event-free survival (EFS) in patients with high-risk neuroblastoma (HRNB) receiving eflornithine (DFMO) maintenance treatment based on a retrospective, blinded independent central review (BICR) of imaging during long-term follow-up
    Oesterheld, Javier E.
    Bergendahl, Genevieve
    Clinch, Thomas
    Gullo, Kristen
    Staines, Harry
    Bohl, Casey E.
    Kraveka, Jacqueline M.
    Ferguson, William
    Sholler, Giselle Linda Saulnier
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] SENSITIVITY ANALYSES OF EVENT FREE AND OVERALL SURVIVAL IN HIGH-RISK NEUROBLASTOMA PATIENTS RECEIVING DFMO MAINTENANCE TREATMENT WITH MATCHED EXTERNAL CONTROLS INCLUDING MYCN
    Sholler, Giselle Saulnier
    Bergendahl, Genevieve
    Ferguson, William
    Clinch, Thomas
    Lorenzi, Elizabeth
    Berry, Donald
    Oesterheld, Javier
    Brown, Valerie
    Eslin, Don
    Hanson, Derek
    Harrod, Virginia
    Isakoff, Michael
    Mitchell, Deanna
    Roberts, William
    Wada, Randal
    Zage, Peter
    Kraveka, Jacqueline
    PEDIATRIC BLOOD & CANCER, 2023, 70 : S90 - S91
  • [8] OXALIPLATIN AND DOXORUBICIN TREATMENT FOR RELAPSED AND REFRACTORY HIGH-RISK NEUROBLASTOMA
    Hung Tran
    Marachelian, Araz
    Venkatramani, Rajkumar
    Jubran, Rima
    Mascarenhas, Leo
    PEDIATRIC BLOOD & CANCER, 2013, 60 : S73 - S73
  • [9] Treatment and Outcomes of Patients With Relapsed, High-Risk Neuroblastoma: Results of German Trials
    Simon, Thorsten
    Berthold, Frank
    Borkhardt, Arndt
    Kremens, Bernhard
    De Carolis, Boris
    Hero, Barbara
    PEDIATRIC BLOOD & CANCER, 2011, 56 (04) : 578 - 583
  • [10] Naxitamab (NAX) treatment for refractory/relapsed (R/R) high-risk neuroblastoma (HRNB): Response data and efficacy in patient (pt) subgroups.
    Mora, Jaume
    Chan, Godfrey Chi-Fung
    Morgenstern, Daniel A.
    Nysom, Karsten
    Bear, Melissa
    Tornoe, Karen
    Sorensen, Per Settergren
    Kushner, Brian H.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345